Observational Study: Application of Therapy with Equine Serum for Patients Diagnosed with COVID-19 in Tucumán, Argentina

Autores
Chahla, Rossana; Medina Ruiz, Luis Antonio; Ferre Contreras, Miguel Enrique; Raya, Mario; Herrera, Natalia; Ortega, Eugenia Silvana; Goroso, Daniel Gustavo; Peral, Maria de Los Angeles
Año de publicación
2022
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Purpose: The objective of this work is to make an observational study of the usage in moderate or severe state COVID-19 patients of a new therapeutic commercial product obtained after immunization of horses: CoviFab® ELEA F(ab´)2 fragmented equine immunoglobulins anti SARS-CoV2. Methods: Participant centers depend on the Public Health System of Tucumán, Argentina were recruitment. Subjects were assigned to the Moderate Patient Group (MPG) and the Severe Patient Group (SPG), classified according to WHO criteria. In total, n=84 were enrolled for this study. The subjects were divided into MPG and SPG. All participants were evaluated by physical examination and COVID-19 infection was diagnosed with positive RT-PCR. Each subject received two doses of 0.16 ml/kg, according to the subject´s body weight. A generalized linear model with binomial distribution was adjusted for the number of symptoms. Data was analysed using proportion, bivariate and logistic regression. P-value was consideredsignificant at the p<0.05 threshold. Results: Both groups were similar in age, sex, and comorbidities. A higher proportion of patient with medical discharge was observed in MPG (91.4%) vs. SPG (55.3%) (p=0.004). MPG showed 9 times more chance of receiving medical discharge than SPG (9.33 CI=[1.65, 52.81]; p=0.012). Then, the chance to get medical discharge was independent of variables sex,age, and comorbidities. Conclusion: Treatment with Equine Serum in patients with moderate and severe disease of COVID-19 managed to slightly reduce hospitalization time. This treatment improved the clinical state to obtain medical discharge. The bivariate analysis showed 8 times more chance in MGP versus SGP to receive of medical discharge and this chance was independentof the pre-existent comorbidities.
Fil: Chahla, Rossana. Provincia de Tucumán. Sistema Provincial de Salud; Argentina
Fil: Medina Ruiz, Luis Antonio. Provincia de Tucumán. Sistema Provincial de Salud; Argentina
Fil: Ferre Contreras, Miguel Enrique. Provincia de Tucumán. Sistema Provincial de Salud; Argentina
Fil: Raya, Mario. Provincia de Tucumán. Sistema Provincial de Salud; Argentina
Fil: Herrera, Natalia. Provincia de Tucumán. Sistema Provincial de Salud; Argentina
Fil: Ortega, Eugenia Silvana. Provincia de Tucumán. Sistema Provincial de Salud; Argentina
Fil: Goroso, Daniel Gustavo. Mogi das Cruzes University; Brasil
Fil: Peral, Maria de Los Angeles. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Tucumán. Instituto Superior de Investigaciones Biológicas. Universidad Nacional de Tucumán. Instituto Superior de Investigaciones Biológicas; Argentina. Provincia de Tucumán. Sistema Provincial de Salud; Argentina
Materia
EQUINE SERUM
COVID-19
MODERATE
SEVERE PATIENT
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/217647
Acceder
id CONICETDig_5d5a17f0fb61e2ac651f2c3714dc6d6a
oai_identifier_str oai:ri.conicet.gov.ar:11336/217647
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Observational Study: Application of Therapy with Equine Serum for Patients Diagnosed with COVID-19 in Tucumán, ArgentinaChahla, RossanaMedina Ruiz, Luis AntonioFerre Contreras, Miguel EnriqueRaya, MarioHerrera, NataliaOrtega, Eugenia SilvanaGoroso, Daniel GustavoPeral, Maria de Los AngelesEQUINE SERUMCOVID-19MODERATESEVERE PATIENThttps://purl.org/becyt/ford/3.2https://purl.org/becyt/ford/3Purpose: The objective of this work is to make an observational study of the usage in moderate or severe state COVID-19 patients of a new therapeutic commercial product obtained after immunization of horses: CoviFab® ELEA F(ab´)2 fragmented equine immunoglobulins anti SARS-CoV2. Methods: Participant centers depend on the Public Health System of Tucumán, Argentina were recruitment. Subjects were assigned to the Moderate Patient Group (MPG) and the Severe Patient Group (SPG), classified according to WHO criteria. In total, n=84 were enrolled for this study. The subjects were divided into MPG and SPG. All participants were evaluated by physical examination and COVID-19 infection was diagnosed with positive RT-PCR. Each subject received two doses of 0.16 ml/kg, according to the subject´s body weight. A generalized linear model with binomial distribution was adjusted for the number of symptoms. Data was analysed using proportion, bivariate and logistic regression. P-value was consideredsignificant at the p<0.05 threshold. Results: Both groups were similar in age, sex, and comorbidities. A higher proportion of patient with medical discharge was observed in MPG (91.4%) vs. SPG (55.3%) (p=0.004). MPG showed 9 times more chance of receiving medical discharge than SPG (9.33 CI=[1.65, 52.81]; p=0.012). Then, the chance to get medical discharge was independent of variables sex,age, and comorbidities. Conclusion: Treatment with Equine Serum in patients with moderate and severe disease of COVID-19 managed to slightly reduce hospitalization time. This treatment improved the clinical state to obtain medical discharge. The bivariate analysis showed 8 times more chance in MGP versus SGP to receive of medical discharge and this chance was independentof the pre-existent comorbidities.Fil: Chahla, Rossana. Provincia de Tucumán. Sistema Provincial de Salud; ArgentinaFil: Medina Ruiz, Luis Antonio. Provincia de Tucumán. Sistema Provincial de Salud; ArgentinaFil: Ferre Contreras, Miguel Enrique. Provincia de Tucumán. Sistema Provincial de Salud; ArgentinaFil: Raya, Mario. Provincia de Tucumán. Sistema Provincial de Salud; ArgentinaFil: Herrera, Natalia. Provincia de Tucumán. Sistema Provincial de Salud; ArgentinaFil: Ortega, Eugenia Silvana. Provincia de Tucumán. Sistema Provincial de Salud; ArgentinaFil: Goroso, Daniel Gustavo. Mogi das Cruzes University; BrasilFil: Peral, Maria de Los Angeles. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Tucumán. Instituto Superior de Investigaciones Biológicas. Universidad Nacional de Tucumán. Instituto Superior de Investigaciones Biológicas; Argentina. Provincia de Tucumán. Sistema Provincial de Salud; ArgentinaOMICS International2022-06info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/217647Chahla, Rossana; Medina Ruiz, Luis Antonio; Ferre Contreras, Miguel Enrique; Raya, Mario; Herrera, Natalia; et al.; Observational Study: Application of Therapy with Equine Serum for Patients Diagnosed with COVID-19 in Tucumán, Argentina; OMICS International; Journal of Infectious Diseases & Therapy; 10; S3; 6-2022; 1-52332-0877CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/https://www.omicsonline.org/open-access/observational-study-application-of-therapy-with-equine-serum-for-patients-diagnosed-with-covid19-in-tucumaacuten-argentina-119547.htmlinfo:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-29T09:57:55Zoai:ri.conicet.gov.ar:11336/217647instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-29 09:57:55.568CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Observational Study: Application of Therapy with Equine Serum for Patients Diagnosed with COVID-19 in Tucumán, Argentina
title Observational Study: Application of Therapy with Equine Serum for Patients Diagnosed with COVID-19 in Tucumán, Argentina
spellingShingle Observational Study: Application of Therapy with Equine Serum for Patients Diagnosed with COVID-19 in Tucumán, Argentina
Chahla, Rossana
EQUINE SERUM
COVID-19
MODERATE
SEVERE PATIENT
title_short Observational Study: Application of Therapy with Equine Serum for Patients Diagnosed with COVID-19 in Tucumán, Argentina
title_full Observational Study: Application of Therapy with Equine Serum for Patients Diagnosed with COVID-19 in Tucumán, Argentina
title_fullStr Observational Study: Application of Therapy with Equine Serum for Patients Diagnosed with COVID-19 in Tucumán, Argentina
title_full_unstemmed Observational Study: Application of Therapy with Equine Serum for Patients Diagnosed with COVID-19 in Tucumán, Argentina
title_sort Observational Study: Application of Therapy with Equine Serum for Patients Diagnosed with COVID-19 in Tucumán, Argentina
dc.creator.none.fl_str_mv Chahla, Rossana
Medina Ruiz, Luis Antonio
Ferre Contreras, Miguel Enrique
Raya, Mario
Herrera, Natalia
Ortega, Eugenia Silvana
Goroso, Daniel Gustavo
Peral, Maria de Los Angeles
author Chahla, Rossana
author_facet Chahla, Rossana
Medina Ruiz, Luis Antonio
Ferre Contreras, Miguel Enrique
Raya, Mario
Herrera, Natalia
Ortega, Eugenia Silvana
Goroso, Daniel Gustavo
Peral, Maria de Los Angeles
author_role author
author2 Medina Ruiz, Luis Antonio
Ferre Contreras, Miguel Enrique
Raya, Mario
Herrera, Natalia
Ortega, Eugenia Silvana
Goroso, Daniel Gustavo
Peral, Maria de Los Angeles
author2_role author
author
author
author
author
author
author
dc.subject.none.fl_str_mv EQUINE SERUM
COVID-19
MODERATE
SEVERE PATIENT
topic EQUINE SERUM
COVID-19
MODERATE
SEVERE PATIENT
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.2
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv Purpose: The objective of this work is to make an observational study of the usage in moderate or severe state COVID-19 patients of a new therapeutic commercial product obtained after immunization of horses: CoviFab® ELEA F(ab´)2 fragmented equine immunoglobulins anti SARS-CoV2. Methods: Participant centers depend on the Public Health System of Tucumán, Argentina were recruitment. Subjects were assigned to the Moderate Patient Group (MPG) and the Severe Patient Group (SPG), classified according to WHO criteria. In total, n=84 were enrolled for this study. The subjects were divided into MPG and SPG. All participants were evaluated by physical examination and COVID-19 infection was diagnosed with positive RT-PCR. Each subject received two doses of 0.16 ml/kg, according to the subject´s body weight. A generalized linear model with binomial distribution was adjusted for the number of symptoms. Data was analysed using proportion, bivariate and logistic regression. P-value was consideredsignificant at the p<0.05 threshold. Results: Both groups were similar in age, sex, and comorbidities. A higher proportion of patient with medical discharge was observed in MPG (91.4%) vs. SPG (55.3%) (p=0.004). MPG showed 9 times more chance of receiving medical discharge than SPG (9.33 CI=[1.65, 52.81]; p=0.012). Then, the chance to get medical discharge was independent of variables sex,age, and comorbidities. Conclusion: Treatment with Equine Serum in patients with moderate and severe disease of COVID-19 managed to slightly reduce hospitalization time. This treatment improved the clinical state to obtain medical discharge. The bivariate analysis showed 8 times more chance in MGP versus SGP to receive of medical discharge and this chance was independentof the pre-existent comorbidities.
Fil: Chahla, Rossana. Provincia de Tucumán. Sistema Provincial de Salud; Argentina
Fil: Medina Ruiz, Luis Antonio. Provincia de Tucumán. Sistema Provincial de Salud; Argentina
Fil: Ferre Contreras, Miguel Enrique. Provincia de Tucumán. Sistema Provincial de Salud; Argentina
Fil: Raya, Mario. Provincia de Tucumán. Sistema Provincial de Salud; Argentina
Fil: Herrera, Natalia. Provincia de Tucumán. Sistema Provincial de Salud; Argentina
Fil: Ortega, Eugenia Silvana. Provincia de Tucumán. Sistema Provincial de Salud; Argentina
Fil: Goroso, Daniel Gustavo. Mogi das Cruzes University; Brasil
Fil: Peral, Maria de Los Angeles. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Tucumán. Instituto Superior de Investigaciones Biológicas. Universidad Nacional de Tucumán. Instituto Superior de Investigaciones Biológicas; Argentina. Provincia de Tucumán. Sistema Provincial de Salud; Argentina
description Purpose: The objective of this work is to make an observational study of the usage in moderate or severe state COVID-19 patients of a new therapeutic commercial product obtained after immunization of horses: CoviFab® ELEA F(ab´)2 fragmented equine immunoglobulins anti SARS-CoV2. Methods: Participant centers depend on the Public Health System of Tucumán, Argentina were recruitment. Subjects were assigned to the Moderate Patient Group (MPG) and the Severe Patient Group (SPG), classified according to WHO criteria. In total, n=84 were enrolled for this study. The subjects were divided into MPG and SPG. All participants were evaluated by physical examination and COVID-19 infection was diagnosed with positive RT-PCR. Each subject received two doses of 0.16 ml/kg, according to the subject´s body weight. A generalized linear model with binomial distribution was adjusted for the number of symptoms. Data was analysed using proportion, bivariate and logistic regression. P-value was consideredsignificant at the p<0.05 threshold. Results: Both groups were similar in age, sex, and comorbidities. A higher proportion of patient with medical discharge was observed in MPG (91.4%) vs. SPG (55.3%) (p=0.004). MPG showed 9 times more chance of receiving medical discharge than SPG (9.33 CI=[1.65, 52.81]; p=0.012). Then, the chance to get medical discharge was independent of variables sex,age, and comorbidities. Conclusion: Treatment with Equine Serum in patients with moderate and severe disease of COVID-19 managed to slightly reduce hospitalization time. This treatment improved the clinical state to obtain medical discharge. The bivariate analysis showed 8 times more chance in MGP versus SGP to receive of medical discharge and this chance was independentof the pre-existent comorbidities.
publishDate 2022
dc.date.none.fl_str_mv 2022-06
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/217647
Chahla, Rossana; Medina Ruiz, Luis Antonio; Ferre Contreras, Miguel Enrique; Raya, Mario; Herrera, Natalia; et al.; Observational Study: Application of Therapy with Equine Serum for Patients Diagnosed with COVID-19 in Tucumán, Argentina; OMICS International; Journal of Infectious Diseases & Therapy; 10; S3; 6-2022; 1-5
2332-0877
CONICET Digital
CONICET
url http://hdl.handle.net/11336/217647
identifier_str_mv Chahla, Rossana; Medina Ruiz, Luis Antonio; Ferre Contreras, Miguel Enrique; Raya, Mario; Herrera, Natalia; et al.; Observational Study: Application of Therapy with Equine Serum for Patients Diagnosed with COVID-19 in Tucumán, Argentina; OMICS International; Journal of Infectious Diseases & Therapy; 10; S3; 6-2022; 1-5
2332-0877
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/url/https://www.omicsonline.org/open-access/observational-study-application-of-therapy-with-equine-serum-for-patients-diagnosed-with-covid19-in-tucumaacuten-argentina-119547.html
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
application/pdf
dc.publisher.none.fl_str_mv OMICS International
publisher.none.fl_str_mv OMICS International
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1844613729610629120
score 13.070432

Publicaciones similares